Ultragenyx announces FDA and EMA granted orphan drug designation for UX003 for the treatment of MPS VII

On February 28, 2012, Ultragenyx Pharmaceutical Inc. announced that the FDA office of Orphan Products Development granted orphan drug designation for UX003 for the treatment of MPS VII. See the full press release for more details.

On March 28, 2012, Ultragenyx announced the European Medicines Agency (EMA) granted orphan drug designation for UX003 for the treatment of MPS VII.  See the full press release for more details.

This entry was posted in News. Bookmark the permalink.

Comments are closed.